Search Results

You are looking at 1 - 10 of 278 items for :

  • liver disease x
Clear All
Open access

Aneta Gawlik, Michael Shmoish, Michaela F Hartmann, Stefan A Wudy, Zbigniew Olczak, Katarzyna Gruszczynska and Ze’ev Hochberg

Introduction Nonsyndromic childhood obesity is associated with nonalcoholic fatty liver disease (NAFLD), a spectrum of conditions, ranging from steatosis to nonalcoholic steatohepatitis (NASH), and various degrees of fibrosis and cirrhosis ( 1

Open access

Jia Li, Yan Zhao, Caoxin Huang, Zheng Chen, Xiulin Shi, Long Li, Zhong Chen and Xuejun Li

Introduction Nonalcoholic fatty liver disease (NAFLD) has become an important public health problem because of its high prevalence with lifestyle improvements. Currently, the principal treatment for NAFLD is lifestyle modification by diet and

Open access

María L Bacigalupo, Verónica G Piazza, Nadia S Cicconi, Pablo Carabias, Andrzej Bartke, Yimin Fang, Ana I Sotelo, Gabriel A Rabinovich, María F Troncoso and Johanna G Miquet

Introduction Liver cancer is the third most common cause of cancer-related deaths worldwide ( 1 ). Hepatocellular carcinoma (HCC) accounts for 90% of liver tumors and it is strongly associated with chronic hepatitis B or C virus infection

Open access

Leanne Hodson and Fredrik Karpe

hepatic metabolism can impact widely on metabolic disease risk. An example of this is the accumulation of intra-hepatocellular fat, which is likely to be due to an imbalance between fatty acid delivery to the liver, fatty acid synthesis within the liver

Open access

Shan Wu, Jianjun Zhou, Jing Guo, Zhan Hua, Jianchen Li and Zai Wang

), particularly in liver metastasis ( 10 ). For this reason, sunitinib, a multi-targeted tyrosine kinase receptor inhibitor of VEGFR1-3, platelet-derived growth factor receptor, mast/stem cell growth factor receptor kit, proto-oncogene tyrosine-protein kinase

Open access

Rachel D C A Diniz, Renata M Souza, Roberto Salvatori, Alex Franca, Elenilde Gomes-Santos, Thiago O Ferrão, Carla R P Oliveira, João A M Santana, Francisco A Pereira, Rita A A Barbosa, Anita H O Souza, Rossana M C Pereira, Alécia A Oliveira-Santos, Allysson M P Silva, Francisco J Santana-Júnior, Eugênia H O Valença, Viviane C Campos and Manuel H Aguiar-Oliveira

Introduction Nonalcoholic fatty liver disease (NAFLD) is a manifestation of the metabolic syndrome and is associated with very common conditions such as obesity, type 2 diabetes, hypertension, dyslipidemia, and atherosclerosis (1) . NAFLD includes

Open access

Frederique Van de Velde, Marlies Bekaert, Anja Geerts, Anne Hoorens, Arsène-Hélène Batens, Samyah Shadid, Margriet Ouwens, Yves Van Nieuwenhove and Bruno Lapauw

Introduction An important complication of obesity is the development of nonalcoholic fatty liver disease (NAFLD), which covers a broad histological spectrum from simple steatosis to nonalcoholic steatohepatitis (NASH), and can progress to

Open access

Jakob Kirkegård, Dora Körmendiné Farkas, Jens Otto Lunde Jørgensen and Deirdre P Cronin-Fenton

pancreatic cancer in hyperthyroid patients compared with their euthyroid counterparts ( 4 ). A case–control study of ~1500 patients suggested an elevated risk of liver cancer associated with hypothyroid disease ( 5 ). Furthermore, in a case–control study of

Open access

Elin Kahlert, Martina Blaschke, Knut Brockmann, Clemens Freiberg, Onno E Janssen, Nikolaus Stahnke, Domenika Strik, Martin Merkel, Alexander Mann, Klaus-Peter Liesenkötter and Heide Siggelkow

, increased liver enzyme values, thyroid abnormalities, sensorineural hearing loss, and inflammatory bowel disease are relatively common in TS ( 3 , 11 , 12 , 13 , 14 , 15 ). In addition, these women also display a tendency to suffer from low bone mineral

Open access

Sandrine Visentin, Gérard Michel, Claire Oudin, Béatrice Cousin, Bénédicte Gaborit, Inès Abdesselam, Marie Maraninchi, Marion Nowicki, René Valéro, Maxime Guye, Monique Bernard, Pascal Auquier, Hervé Chambost, Marie-Christine Alessi and Sophie Béliard

be protective against NAFLD (nonalcoholic fatty liver disease) ( 35 ). Similarly, we observed a significantly higher rate of liver steatosis associated with a lower BMI, and a trend toward decreased TAT and SAT after TBI in patients who had been